State Street discloses 5.1% stake in Ultragenyx
State Street Corporation reported beneficial ownership of 5,021,441 shares of Ultragenyx Pharmaceutical Inc. common stock, representing 5.1% of the class as of 03/31/2026.
Rhea-AI Filing Summary
State Street Corporation reported beneficial ownership of 5,021,441 shares of Ultragenyx Pharmaceutical Inc. common stock, representing 5.1% of the class as of 03/31/2026. The filing lists shared voting power of 4,769,004 shares and shared dispositive power of 5,021,441 shares. The filing is a Schedule 13G disclosure signed on 05/12/2026 by Elizabeth Schaefer.
Positive
- None.
Negative
- None.
Insights
State Street holds a passive 5.1% stake in Ultragenyx as of 03/31/2026.
State Street Corporation's Schedule 13G reports 5,021,441 shares beneficially owned with shared voting power 4,769,004 and shared dispositive power 5,021,441. Schedule 13G status typically indicates passive investment intent under SEC rules.
Cash‑flow treatment and any plans to buy or sell are not stated in the excerpt; subsequent filings will show changes in ownership or voting if they occur.
Shared powers imply holdings managed through advisory or pooled vehicles.
The filing names multiple State Street advisory and trust entities (for example, SSGA Funds Management, Inc.), consistent with institutional management of client assets where voting/dispositive rights are exercised on a shared basis.
Investors tracking ownership concentration should note the 5.1% threshold disclosure and watch for any Schedule 13D or Form 4 filings that would signal activist intent or insider transactions.
Key Figures
Key Terms
Schedule 13G regulatory
Beneficially owned financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake does State Street Corporation report in ULTRAGENYX (RARE)?
Which State Street entities are identified in the filing for RARE holdings?
AI-generated analysis. How Rhea-AI works. Not financial advice.